While results in breast cancer patients are still preliminary, the convergence of mechanistic and early clinical data suggests that targeting the IL-1β axis (inflammasome inhibitors, IL-1 blockers) could become a novel strategy to prevent metastatic progression in high-risk breast cancer (e.g., triple-negative tumors with inflammatory signatures). Here, IL1B is linked to breast carcinoma.